Cytosorbents (CTSO) Assets Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.96% |
| Dec 31, 2025 | -11.26% |
| Sep 30, 2025 | -9.77% |
| Jun 30, 2025 | -12.32% |
| Mar 31, 2025 | -15.20% |
| Dec 31, 2024 | -19.11% |
| Sep 30, 2024 | -20.48% |
| Jun 30, 2024 | -18.36% |
| Mar 31, 2024 | -18.66% |
| Dec 31, 2023 | -16.19% |
| Sep 30, 2023 | -23.02% |
| Jun 30, 2023 | 2.11% |
| Mar 31, 2023 | 9.12% |
| Dec 31, 2022 | 32.18% |
| Sep 30, 2022 | 29.49% |
| Jun 30, 2022 | 35.72% |
| Mar 31, 2022 | 39.02% |
| Dec 31, 2021 | 37.82% |
| Sep 30, 2021 | 40.54% |
| Jun 30, 2021 | 41.11% |
| Mar 31, 2021 | 45.66% |
| Dec 31, 2020 | 55.11% |
| Sep 30, 2020 | 67.43% |
| Jun 30, 2020 | 30.65% |
| Mar 31, 2020 | 74.74% |
| Dec 31, 2019 | 41.36% |
| Sep 30, 2019 | 38.24% |
| Jun 30, 2019 | 30.86% |
| Mar 31, 2019 | 48.25% |
| Dec 31, 2018 | 44.84% |
| Dec 31, 2017 | 41.72% |
| Sep 30, 2017 | 32.15% |
| Jun 30, 2017 | 25.19% |
| Mar 31, 2017 | -12.55% |
| Dec 31, 2016 | 33.81% |
| Sep 30, 2016 | 39.05% |
| Jun 30, 2016 | 62.16% |
| Mar 31, 2016 | 55.56% |
| Dec 31, 2015 | 49.93% |
| Dec 31, 2014 | 58.61% |
| Sep 30, 2014 | 48.59% |
| Jun 30, 2014 | 42.84% |
| Dec 31, 2013 | 30.70% |